Table 2.
Baseline characteristics of the patients according to the optimal cut-off value of the TyG index
| Variable | the Tyg index ≤ 9.04 (n = 315) | the Tyg index > 9.04 (n = 318) | P value |
|---|---|---|---|
| Age, years | 69.31 ± 10.54 | 66.75 ± 10.81 | 0.003 |
| Female | 101 (32.1) | 1.7 (33.6) | 0.671 |
| BMI, kg/m2 | 24.60 ± 2.93 | 25.19 ± 3.24 | 0.016 |
| Smoking, n (%) | 136 (43.2) | 148 (46.5) | 0.395 |
| Previous PCI, n (%) | 35 (11.1) | 33 (10.4) | 0.766 |
| COPD, n (%) | 15 (4.8) | 13 (4.1) | 0.680 |
| Hypertension, n (%) | 234 (74.3) | 243 (76.4) | 0.534 |
| AF, n (%) | 21 (6.7) | 31 (9.7) | 0.158 |
| Previous Stroke, n (%) | 18 (5.7) | 18 (5.7) | 0.977 |
| SBP, mmHg | 133.36 ± 22.64 | 133.96 ± 21.30 | 0.731 |
| HR, bpm | 77.43 ± 13.92 | 80.12 ± 15.69 | 0.023 |
| cTnT, pg/ml | 26.80 (13.50, 408.80) | 38.84 (13.33, 604.93) | 0.170 |
| BNP, pg/ml | 92.80 (39.20, 294.00) | 130.00 (44.63, 462.81) | 0.065 |
| Scr (umol/L) | 79.00 (67.00, 96.20) | 76.10 (63.00, 100.98) | 0.614 |
| FBG (mmol/L) | 7.08 ± 2.10 | 9.67 ± 3.29 | < 0.001 |
| HbA1c | 7.26 ± 1.61 | 7.93 ± 1.76 | < 0.001 |
| TG (mmol/L) | 1.11 ± 0.33 | 2.01 ± 1.02 | < 0.001 |
| TC (mmol/L) | 4.10 ± 1.16 | 4.67 ± 1.31 | < 0.001 |
| HDL-C (mmol/L) | 1.13 ± 0.30 | 1.12 ± 0.29 | 0.466 |
| LDL-C (mmol/L) | 2.47 ± 0.80 | 2.86 ± 0.93 | < 0.001 |
| LVEF | 55.04 ± 9.50 | 55.11 ± 9.90 | 0.226 |
| AMI, n (%) | 130 (41.3) | 154 (48.4) | 0.070 |
| Diagnosis,n (%) | 0.150 | ||
| CCS | 52 (16.5) | 38 (11.9) | |
| UA | 133 (42.2) | 126 (39.6) | |
| NSTEMI | 70 (22.2) | 74 (23.3) | |
| STEMI | 60 (19.0) | 80 (25.2) | |
| Aspirin, n (%) | 309 (98.1) | 304 (95.6) | 0.072 |
| P2Y12 receptor inhibitor, n (%) | 313 (99.4) | 313 (98.4) | 0.259 |
| Statins, n (%) | 307 (97.5) | 311 (97.8) | 0.780 |
| β-blockers, n (%) | 214 (67.9) | 238 (74.8) | 0.055 |
| ACEI/ARB, n (%) | 151 (47.9) | 169 (53.1) | 0.190 |
| Diuretics, n (%) | 62 (19.7) | 77 (24.2) | 0.169 |
| Insulin, n (%) | 74 (23.5) | 93 (29.2) | 0.101 |
| Oral hypoglycemic agents, n (%) | 220 (69.8) | 230 (72.3) | 0.490 |
| MVD, n (%) | 227 (72.1) | 246 (77.4) | 0.125 |
| LM, n (%) | 24 (7.6) | 21 (6.6) | 0.619 |
| Calcified lesions, n (%) | 58 (18.4) | 61 (19.2) | 0.804 |
| Thrombosis, n (%) | 28 (8.9) | 30 (9.4) | 0.812 |
| Long lesion, n (%) | 193 (61.3) | 203 (63.8) | 0.504 |
| CTO, n (%) | 62 (19.7) | 77 (24.2) | 0.169 |
| Number of stents | 1.55 ± 0.94 | 1.53 ± 0.94 | 0.780 |
| Length of stents, mm | 40.54 ± 27.65 | 41.09 ± 28.50 | 0.805 |
| Tyg index | 8.65 ± 0.33 | 9.50 ± 0.40 | < 0.001 |
| bSS | 15.00 (9.00,21.00) | 15.75 (9.00,21.50) | 0.458 |
| rSS | 4.00 (0.00,8.00) | 4.25 (1.00,9.00) | 0.327 |
The groups were stratified by the optimal cutoff value of the TyG index to measure MACEs, which was determined by receiver‑operating characteristic curve analysis. Data are presented as mean ± SD, median (IQR) or n (%)
MACEs major adverse cardiac events, BMI body mass index, PCI percutaneous coronary intervention, COPD chronic obstructive pulmonary disease, AF atrial fibrillation, SBP systolic blood pressure, HR heart rate, BNP brain natriuretic peptide, Scr serum creatinine, FBG fasting blood glucose, TG triglyceride, TC total cholesterol, HDL high density lipoprotein, LDL low density lipoprotein, LVEF left ventricular ejection fraction, AMI acute myocardial infarction, CCS chronic coronary syndrome, UA unstable angina, STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction, ACEI/ARB angiotensin converting enzyme inhibitor/angiotensin receptor blocker, MVD multivessel disease, LM left main disease, CTO chronic total occlusion, TyG index the triglyceride–glucose index, bSS baseline SYNTAX score, rSS residual SYNTAX score.